BioNTech beat earnings and revenue expectations as the Omicron variant spurred strong demand for its Covid-19 vaccine developed with Pfizer.
The German biotech company, which launched the first Covid vaccine in partnership with the US pharmaceuticals group, reported first-quarter revenue of €6.4bn, more than triple the figure from the same period the year before, and higher than the average analyst estimate of €4.6bn.
Diluted earnings per share more than tripled to €14.24, higher than the consensus forecast for €9.71. Net profit was €3.7bn, compared with €1.1bn a year earlier.
您已閱讀21%（581字），剩余79%（2156字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。